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Abstract
Background: The potential for HIV transmission between a pregnant woman and her unborn child was first
recognized in 1982. Since then a complex package of measures to reduce risk has been developed. This project aims
to review UK management of HIV in pregnancy as part of the British HIV Association (BHIVA) audit programme.
Methods: The National Study of HIV in Pregnancy and Childhood (NSHPC), a population-based surveillance study,
provided data for pregnancies with an expected delivery date from 1/1/13 - 30/6/14. Services also completed a survey
on local management policies. Data were audited against the 2012 BHIVA pregnancy guidelines.
Results: During the audit period 1483 pregnancies were reported and 112 services completed the survey. Use of
dedicated multidisciplinary teams was reported by 99% although 26% included neither a specialist midwife nor nurse.
17% of services reported delays >1 week for HIV specialist review of women diagnosed antenatally. Problematic urgent
HIV testing had been experienced by 9% of services although in a further 49% the need for urgent testing had not
arisen. Delays of >2 h in obtaining urgent results were common.
Antiretroviral therapy (ART) was started during pregnancy in 37% women with >94% regimens in accordance with
guidelines. Late ART initiation was common, particularly in those with a low CD4 count or high viral load.
Eleven percent of services reported local policy contrary to guidelines regarding delivery mode for women with a
VL <50 copies/mL at ≥36 weeks. According to NSHPC reports 27% of women virologically eligible for vaginal delivery
planned to deliver by CS.
Conclusions: Pregnant women in the UK are managed largely in accordance with BHIVA guidelines. Improvements
are needed to ensure timely referral and ART initiation to ensure the best possible outcomes.
Keywords: HIV, Mother to child transmission, Vertical transmission
Background
The potential for HIV transmission from a pregnant
woman to her unborn child was recognized in 1982,
prior even to the identification of the HIV virus [1].
Since this time significant advances have been made in
our knowledge of methods to reduce this risk. The
dramatic reduction in transmission rate in the UK and
Ireland from 25.6% in the 1990s [2] to 0.5% in 2011 [3]
demonstrates the success of these interventions.
Prevention of mother to child transmission (MTCT) is
complex: interventions aim to reduce risk throughout
pregnancy, labour, delivery and the neonatal period.
Consequently a specialist multi-disciplinary team,
including HIV clinicians, midwives, obstetricians and
paediatricians is a valuable tool. Approximately 1300
women with HIV have given birth annually in the UK
since 2004 [4]. Areas of concentrated prevalence exist,
particularly within London, while for some centres
caring for a pregnant woman with HIV is a rare event.
In addition to preventing HIV transmission, implement-
ing these interventions is also beneficial for maternal
health. Universal antenatal screening facilitates diagnosis
of those living with unknown HIV. Pregnancy can also act
as a trigger to review management, improve engagement
and provide additional care to those with a known HIV
diagnosis. Regular specialist multi-disciplinary review can
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help identify any pregnancy or HIV related complications
and also provide psychological support where required.
Surveillance of paediatric HIV and HIV in pregnancy
has been ongoing in the UK and Ireland since 1986 and
1989 respectively, through the mechanisms of the
National Study of HIV in Pregnancy and Childhood
(NSHPC), described in detail elsewhere [3].
Since 2001 the British HIV Association (BHIVA) has
produced guidelines to support clinicians in the delivery
of care aimed at reducing MTCT. These guidelines have
been reviewed regularly and updated. The aim of this
audit was to review the UK management of HIV in preg-
nancy in comparison with the 2012 BHIVA guidelines.
Methods
NSHPC provided BHIVA with data for pregnancies with
an expected date of delivery between 1/1/13 and 30/6/
14. The data included demographic and clinical details,
timing of HIV diagnosis, viral load, CD4 count and anti-
retroviral treatment (ART) in pregnancy, whether sexual
health screening had been offered in pregnancy, and
mode of delivery; no patient identifiers were provided to
BHIVA. In addition, pregnancy-lead clinicians for all
HIV services throughout the UK were invited by the
BHIVA audit group to complete a survey detailing local
arrangements for the management of pregnancy in HIV.
They were encouraged to complete the survey with in-
put from local HIV-lead obstetricians and paediatri-
cians (Additional file 1).
Pseudonymised data were stored and analysed in a
password protected, encrypted Microsoft excel spread-
sheet. Data were audited against the 2012 BHIVA
guidelines for the management of HIV in pregnancy [5].
Ethical approval and informed consent were not re-
quired as this study was a clinical audit based on rou-
tinely collected data [6].
Results
1483 pregnancies were reported during the audit period
and 112 HIV services completed the survey (Table 1).
The 1483 pregnancies occurred in 1469 women, the ma-
jority of whom were of Black African ethnicity (1089,
73.7%). 1251 women (85.2%) acquired HIV through het-
erosexual sex, 17 (1.2%) via injecting drug use and 21
(1.4%) as a consequence of MTCT. Route of transmis-
sion was unknown in 180 (12.3%). Median age at ex-
pected date of delivery was 33 years (range 16 – 50).
Of the 1483 pregnancies, 1263 (85.2%) occurred in
women already known to be HIV positive at conception,
217 (14.6%) were to women diagnosed with HIV during
their pregnancy and in three (0.2%) cases timing of HIV
diagnosis was unclear (Table 2). Of the 1263 pregnancies
in women with a pre-existing HIV diagnosis, 920 (73%)
conceived while established on antiretroviral therapy
(ART). An HIV viral load was available between 0 and
16 weeks gestation in 612 women (66.5%) who con-
ceived on ART of whom 87.7% (537) were suppressed to
≤50 copies/mL. Of the 217 women diagnosed in the
index pregnancy, 198 (91.2%) were diagnosed in the
antenatal clinic, 14 were diagnosed elsewhere and in five
cases place of diagnosis was not reported. The majority
of antenatal diagnoses (140, 65%) were made before
16 weeks gestation. Only seven (3%) women were
diagnosed after 36 weeks gestation: six following late
pregnancy booking including one woman who presented
in labour. In one case a woman declined antenatal test-
ing but was later diagnosed by non-maternity services
following presentation with symptomatic HIV.
Multidisciplinary teams
BHIVA guidelines recommend the use of dedicated multi-
disciplinary teams in the delivery of antenatal HIV care.
As a minimum these teams should comprise an HIV
specialist, obstetrician, specialist midwife and paediatri-
cian. One hundred and eleven (99%) services reported a
dedicated multidisciplinary team (MDT) although 29
(26%) included neither a specialist midwife nor nurse.
Nineteen (17%) centres reported delay of > 1 week be-
tween women being diagnosed with HIV via routine ante-
natal screening and receiving specialist HIV assessment.
Urgent HIV testing
BHIVA recommends urgent HIV testing in cases where
a woman without a documented HIV test result presents
in labour, following rupture of membranes or with other
reasons to expedite delivery. Ninety-five (84.8%) HIV
services reported arrangements in place for urgent la-
boratory testing although only 15 (13.4%) services re-
ported access to point of care testing (POCT). Problems
with urgent HIV testing were reported by 10 (8.9%) ser-
vices although in a further 55 (49.1%) services the need
for urgent testing was not reported to have arisen. De-
lays of >2 h in obtaining urgent test results were re-
ported by 21 (18.8%) services in working hours and 56
(50%) out of hours.
Antiretroviral therapy
One hundred and nine (97.4%) services reported the use
of a local ART in pregnancy policy. Two services did not
have a local policy and one service did not respond. In
920 (62.5%) pregnancies the woman was taking ART
when she conceived. In this situation BHIVA recom-
mends that women should remain on their current
regimen unless on protease inhibitor monotherapy or a
regimen containing stavudine (d4T) or didanosine
(DDI). Data regarding continuation of established ART
regimen was not available although this figure is likely to
be high.
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In 552 pregnancies ART was started after conception.
The BHIVA-recommended ART regimens vary depend-
ing on maternal need for ART (a CD4 cell count ≤350
cells/mm3 was used as a surrogate marker in this audit
as full clinical information was not available) or if the
main indication for treatment is to prevent MTCT.
Baseline maternal viral load (VL) also impacts on choice
of agent. Overall accordance with BHIVA recommended
regimens was very high at 93% in those requiring ART
for maternal health and over 98% for those requiring
ART solely to prevent MTCT (Table 3). Information re-
garding previous ART treatment was not available so in
Table 1 Summary of survey results
Does your service have a dedicated HIV in pregnancy MDT?
Yes 111 (99%)
No 1 (1%)
Does this MDT include:
An HIV physician 112 (100%)
An obstetrician 111 (99%)
A paediatrician 110 (98%)
An HIV midwife 29 (26%)
An HIV clinical nurse specialist 21 (19%)
Following a new HIV diagnosis during antenatal screening, how quickly
would you expect a women to be seen in the HIV clinic?
Same/next day 40 (36%)
2 – 3 days 23 (21%)
Within a week 29 (26%)
1 - 2 weeks 19 (17%)
Not answered 1 (1%)
Do you have a policy for the use of ART in pregnancy?
Yes 109 (97%)
No 2 (2%)
No response 1 (1%)
Would you use raltegravir in a women presenting after 28 weeks
gestation with a VL > 100,000 copies/mL?
Use routinely 56 (50%)
May use 43 (38%)
No policy/has not arisen 11 (10%)
Would not use 1 (1%)
Not sure 1 (1%)
What arrangement do you have in place for urgent HIV testing for
women presenting in labour, with ruptured membranes of requiring
delivery with no result?
Arrangement for urgent lab test 95 (85%)
Point of care testing in all delivery units 15 (13%)
Urgent lab test not available 1 (1%)
Not sure 1 (1%)
Have you experienced problems with urgent HIV testing?
Problems experienced 10 (9%)
Provided without problems 40 (36%)
Need not arisen 55 (49%)
How long does it take to obtain an urgent HIV laboratory test result?
>2 h in working hours 21 (19%)
>2 h outside of working hours 56 (50%)
Do you have a policy on mode of delivery in HIV?
Yes 107 (96%)
No 2 (2%)
Not sure/not answered 3 (3%)
Table 1 Summary of survey results (Continued)
What mode of delivery would you recommend for those on ART with a
VL <50 copies/mL at >36 weeks, and no relevant obstetric factors?
Planned vaginal delivery 95 (85%)
Maternal choice 9 (8%)
Pre-labour caesarean section 3 (3%)
Other/not answered 5 (5%)
MDT multidisciplinary team, ART antiretroviral therapy
Table 2 Baseline characteristics
Number of women/pregnanciesa (%)
Ethnicity
Black African 1083 (73.7%) women
White 250 (17%) women
Black Caribbean 46 (3.1%) women
Other/ not stated 90 (6.1%) women
Age at EDDb
16 – 19 12 (0.8%) women
20 – 29 344 (23.4%) women
30 – 39 952 (64.8%) women
40 + 161 (11%) women
HIV acquisition
Heterosexual 1251 (85.2%) women
MTCT 21 (1.4%) women
Injecting drug use 17 (1.2%) women
Other/ not stated 180 (12.3%) women
Timing of HIV diagnosis
Pre-conception 1263 (85.2%) pregnancies
During pregnancy 217 (14.6%) pregnancies
Not stated 3 (0.2%) pregnancies
ART status
Conceived on ART 920 (62%) pregnancies
Conceived off ART 549 (37%) pregnancies
Unclear 14 (0.9%) pregnancies
a1483 pregnancies in 1469 women were reported in the audit period
bFirst EDD for women with two pregnancies
Raffe et al. BMC Infectious Diseases  (2017) 17:158 Page 3 of 6
some cases deviation from guidelines could be explained
by previous failed ART regimens.
BHIVA guidelines recommend that women requiring
ART for maternal health should commence treatment as
soon as possible and within two weeks of diagnosis. Of
the 214 women requiring ART for maternal health,
105 (%) were diagnosed during pregnancy. Of these
women only 30 (29%) commenced ART within the two-
week target with 25 (23.8%) starting 15 – 28 days follow-
ing diagnosis and 43 (41.%) starting >28 days. In seven
cases (6.6%) the start date was not recorded. Delay in
treatment initiation cannot be explained solely by
concerns regarding ART use in the first trimester as only
25/68 (36.8%) women were diagnosed in this period.
BHIVA recommend that all women starting ART during
pregnancy should start treatment by the beginning of
week 24 gestation and those with a VL >30,000 copies/mL
by 16 weeks gestation. Data regarding timing of initiation
was available in 523 pregnancies: 402 (76.6%) with a
baseline VL <30,000 copies/mL (those with an unreported
baseline VL were also included in this group) and
121 (23.4%) with a baseline VL >30,000 copies/ml. Of the
402 pregnancies where ART should have been initiated by
week 24, 318 (79.1%) were managed in accordance with
guidelines and 84 (20.9%) started ART after 24 weeks.
Compliance with guidance was worse in the 121 pregnan-
cies where ART should have commenced by week 16,
where only 47 (38.8%) started ART on time, 56 (46.3%)
started between 16 – 24 weeks gestation and 18 (14.9%)
did not start until after 24 weeks. Of the 158 pregnancies
where ART initiation was late, only 54 could be attributed
to late booking, two to seroconversion and two to both
seroconversion and late booking (Table 4).
Mode of delivery
At point of analysis 1354 pregnancies had resulted in a
live birth, five in stillbirth and in 124 pregnancies the
outcome had yet to be reported. Planning for appropri-
ate mode of delivery is an important factor in the pre-
vention of MTCT and recommendations are dependent
on the maternal VL at or after 36 weeks. Despite this a VL
at this time point was reported in only 613 (45%) pregnan-
cies. Only 106 women delivered prior to 36 weeks. The
2012 BHIVA guidelines recommend vaginal delivery for
women on ART with an HIV VL <50 copies/mL at
36 weeks gestation. When surveyed, 95/112 (84.8%) HIV
services stated they would plan for a vaginal delivery in
this circumstance, nine (8%) stated they would be guided
by maternal choice, three (2.7%) would plan for an elective
caesarean and five (4.5%) did not respond. In the audit
period 540 women had a VL of <50 copies at ≥36 weeks of
whom 391 (72%) planned a vaginal delivery, 148 (27%) a
caesarean and one (<1%) had no reported plan. Where
women have a VL of 50–399 copies/mL at ≥36 weeks,
BHIVA recommend that a vaginal delivery be considered
taking individual factors into account. Fifty women fell
into this category of whom 24 (48%) planned a vaginal de-
livery and 26 (52%) a caesarean section. All women with a
VL ≥400 copies/mL at ≥36 weeks are advised to have a
caesarean section. Twenty-four women were in this group,
19 (79.2%) of whom planned for a caesarean section, three
(12.5%) initially planned for vaginal delivery but had cae-
sarean sections, and two (8.3%) did not have a plan as one
woman was diagnosed with HIV in labour and the second
woman did not attend for antenatal care prior to the onset
of labour.
Actual mode of delivery was vaginal in 630 (46.5%), via
caesarean section in 719 (53.1%) and not reported in 5
(0.4%) live births. Emergency caesarean section rates
were high, occurring in 249 (28.0%) of those planning a
vaginal delivery, 88 (20.9%) of those planning an elective
caesarean section and in 26 (60.5%) of women with no
reported plan. Three women delivered vaginally with a
VL ≥400 copies/mL at >37 weeks, comprising the two
late presenters mentioned above and a woman who
planned caesarean section on ART but had a spontan-
eous vaginal delivery. A further 26 women delivered
vaginally for whom VL data were not available.
Discussion
Main findings
This audit has provided a valuable review of the current
management of HIV in pregnancy in the UK. The results
have been largely encouraging, particularly regarding the
use of multi-disciplinary teams and choice of antiretro-
viral regimen.
Table 3 Choice of antiretroviral regimen
CD4 count (cells/mm3) Viral load (copies/mL) BHIVA recommendationa Number of women In accordance with
recommendation
≤350 - TVD/FTC, ABC/3TC or ZDV/3TC + EFV, NVP or bPI 214 93%
>350 >100,000 TFV/FTC, ABC/3TC or ZDV/3TC + bPI 11 100%
10,000 – 100,000 As above or ZDV/3TC/ABC 81 99%
<10,000 As above or ZDV monotherapy 162 98%
unknown - 84 -
TVD truvada, FTC emtricitabine, ABC abacavir, 3TC lamivudine, ZDV zidovudine, EFV efavirenz, NVP nevirapine, bPI boosted protease inhibitor
aRaltegravir was accepted as an alternative to EFV/NVP/bPI when started after the first trimester
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While the vast majority of women were treated with
an antiretroviral regimen in accordance with guidelines,
the frequent delay seen in initiating treatment is of con-
cern. Only 29% of women diagnosed in pregnancy with
a maternal need for ART were started within the recom-
mended two weeks. This leaves a significant proportion
of women at increased and unnecessary risk of HIV re-
lated morbidity and mortality. In addition this audit has
identified important failings in starting ART by recom-
mended gestational cut-offs, particularly where the viral
load was very high. It is well recognized that maternal
viral load at delivery is the best predictor of perinatal
transmission [7, 8]. The need for timely initiation of
ART was demonstrated by a multicenter UK study
where only 46% of the women with a VL in the upper
quartile (>32,641 copies/mL) achieved viral suppression
when commencing ART at a median gestation of
23 weeks [9]. Any perceived risk of congenital abnor-
mality as a consequence of early ART has not been
confirmed by research studies. The NSHPC reviewed
rates of congenital abnormality occurring in 8576 preg-
nancies between 1990 and 2007. It found an abnormality
rate of 2.8%, consistent with that seen nationally [10].
The reported poor access to reliable urgent HIV testing
is also of major concern. While uptake of antenatal screen-
ing, introduced as a universal recommendation in 2000, is
consistently high at >90% in all regions throughout the UK
[11], it is essential that units are able to confirm HIV status
in cases where a woman presents late or where an earlier
test has been declined. Intrapartum ART is a valuable tool
in late diagnosis [12, 13] and knowledge of a mother’s
status also ensures access to neonatal post-exposure
prophylaxis and follow-up. The use of POCT was particu-
larly low at 13.4%. A further survey exploring the barriers
to use of POCT would be valuable as expanding availability
of POCT may help to solve some of the logistical issues
units face in providing rapid testing out of hours.
Strengths and limitation
This strength of this audit lies in the very high rates of
reporting to the NSHPC, allowing insight into practice
throughout the UK including units based in low HIV
prevalent areas. Nevertheless, there have been limitations
to this audit. Lack of reported viral load data was particu-
larly significant in reviewing planned mode of delivery
where this measurement was only reported in 49% (613/
1248) of pregnancies that had reached 36 weeks gestation
at time of analysis. We were also unable to access either
medical or obstetric history which may have given insight
into decisions regarding antiretroviral therapy or mode of
delivery that did not follow BHIVA recommendations.
Data for this audit was obtained from the standard data
collected by the NSHPC rather than via additional means.
This was advantageous as response rates to the NSHPC are
very high and therefore reflect national practice well and it
also removed the need for additional and time-consuming
data collection by the individual services. However, as a
consequence of this some information that would have
allowed for greater interpretation of the results is lacking.
For example the NSHPC do not routinely collect the previ-
ous ART history from women and therefore it was not pos-
sible to establish if some women were started on ART that
deviated from the guidelines as a consequence of previous
failed regimens or drugs. Likewise it is not possible to ex-
plain why delays in initiating ARVs were seen and whether
this can be attributed to referral pathways, a lack of urgency
or the need for additional pre-treatment diagnostics.
Interpreting the high reported rates of both planned
and elective caesarean is difficult due to the lack of ob-
stetric history. The proportion of second or subsequent
pregnancies in women with HIV is increasing and many
women will have had a previous caesarean section in ac-
cordance with earlier guidelines. Early evidence that an
elective caesarean section reduced risk of HIV transmis-
sion by >50% [14] has since evolved with the introduc-
tion of combination ART and multiple studies have
since shown the rate of MTCT to be <0.5% irrespective
of delivery mode when VL <50 copies/mL [15, 16].
BHIVA guidelines have evolved accordingly and since
2005 have recommended that vaginal delivery should be
considered in all those with a VL <50 copies/mL at or after
36 weeks gestation. In 2012 this was expanded to allow
consideration of vaginal delivery for those with a VL <400
copies/mL considering actual VL, trajectory of VL, ART
duration and adherence and the woman’s views [5].
Conclusion
This audit demonstrates a need for services to review
their ability to access urgent HIV testing, to strengthen
referral pathways between general and specialist ante-
natal care services and to identify where delays in start-
ing women on ART are occurring. It is also important to
ensure that local policy is kept up to date with national
guidance to ensure women are able to access the best
possible care available.








CD4≤ 350a Within 14 days of
HIV diagnosis
105 30 (28.6)
VL <30,000b copies/mL By week 24
gestation
402 318 (79.1)
VL >30,000 copies/mL By week 16
gestation
121 47 (38.8)
aWomen diagnosed with HIV during antenatal period
bAlso includes women who conceived off ART where viral load was
not reported
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Additional file
Additional file 1: List of BHIVA Audit participants. The supplementary
document lists the units across the United Kingdom that completed the
survey detailing local management of HIV in pregnancy. (DOCX 130 kb)
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